Talabi MB, et al. - Among a cohort of reproductive-age women, aged 18 to 50 years, with rheumatic diseases, researchers determined contraception use via conducting a study of administrative data from a single, large medical center between the years 2013 and 2014. Participants in the study were women who had 1 of 21 possible rheumatic disease diagnoses and had at least 2 outpatient rheumatology visits. To assess adjusted associations between the use of prescription contraception, use of potentially fetotoxic medications, and visits with rheumatologists, primary care providers, and gynecologists, logistic regression analyses were used. Of this sample 2,455 women, 32.1% received any prescription contraception, and 7.9% of women used highly effective prescription methods (intrauterine devices, implants, and surgical sterilization). During the 2-year study timeframe, more than 70% of women took ≥1 type of fetotoxic medication. The use of fetotoxic medication was not correlated with the overall use of prescription contraception but was related to the use of highly effective methods of contraception. Women who have seen gynecologists or primary care providers have been more probable to use overall prescription contraception. Women who saw gynecologists were more likely to use contraceptive methods that were highly vs moderately effective. This is the biggest research to date to describe contraceptive use among females with rheumatic diseases of reproductive age, and results show low use of prescription contraception. For some females with rheumatic illnesses, urgent attempts are required to enhance contraceptive care and access. The use of prescription contraception in any models was not connected with rheumatology visits.